BIIB
Price
$199.06
Change
+$3.10 (+1.58%)
Updated
Jun 4, 02:04 PM (EDT)
Capitalization
27.88B
42 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$167.64
Change
+$2.53 (+1.53%)
Updated
Jun 4, 02:04 PM (EDT)
Capitalization
16.6B
61 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIIB vs NBIX

Header iconBIIB vs NBIX Comparison
Open Charts BIIB vs NBIXBanner chart's image
BIIB vs NBIX Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7.81B. The market cap for tickers in the group ranges from 658 to 182.54B. AMGN holds the highest valuation in this group at 182.54B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was -3%. For the same Theme, the average monthly price growth was 2%, and the average quarterly price growth was 0%. REPL experienced the highest price growth at 112%, while HRTX experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -49%. For the same stocks of the Theme, the average monthly volume growth was -2% and the average quarterly volume growth was 29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 68
Price Growth Rating: 55
SMR Rating: 85
Profit Risk Rating: 88
Seasonality Score: 24 (-100 ... +100)

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB).

Market Cap

The average market capitalization across the group is 22.24B. The market cap for tickers in the group ranges from 16.6B to 27.88B. BIIB holds the highest valuation in this group at 27.88B. The lowest valued company is NBIX at 16.6B.

High and low price notable news

The average weekly price growth across all stocks in the group was 3%. For the same group, the average monthly price growth was 14%, and the average quarterly price growth was 7%. NBIX experienced the highest price growth at 6%, while BIIB experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the group was 87%. For the same stocks of the group, the average monthly volume growth was 52% and the average quarterly volume growth was 45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 74
P/E Growth Rating: 51
Price Growth Rating: 45
SMR Rating: 61
Profit Risk Rating: 71
Seasonality Score: 17 (-100 ... +100)
VS
BIIB vs. NBIX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and NBIX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2026
Stock price -- (BIIB: $195.96 vs. NBIX: $165.05)
Brand notoriety: BIIB: Notable vs. NBIX: Not notable
BIIB represents the Pharmaceuticals: Major, while NBIX is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIIB: 72% vs. NBIX: 157%
Market capitalization -- BIIB: $27.88B vs. NBIX: $16.6B
BIIB [@Pharmaceuticals: Major] is valued at $27.88B. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $16.6B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $961.99B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $178.43B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileBIIB’s FA Score has 1 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • BIIB’s FA Score: 1 green, 4 red.
According to our system of comparison, NBIX is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 6 TA indicator(s) are bullish while NBIX’s TA Score has 6 bullish TA indicator(s).

  • BIIB’s TA Score: 6 bullish, 4 bearish.
  • NBIX’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than NBIX.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -0.51% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +5.92% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.64%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +2.80%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.75%. For the same industry, the average monthly price growth was +26.44%, and the average quarterly price growth was +20.27%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 16, 2026.

NBIX is expected to report earnings on Aug 04, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+2.64% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Pharmaceuticals: Generic (-0.75% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($27.9B) has a higher market cap than NBIX($16.6B). NBIX has higher P/E ratio than BIIB: NBIX (25.39) vs BIIB (21.07). NBIX YTD gains are higher at: 16.372 vs. BIIB (11.347). BIIB has higher annual earnings (EBITDA): 2.7B vs. NBIX (829M). BIIB has more cash in the bank: 4.28B vs. NBIX (1.32B). NBIX has less debt than BIIB: NBIX (406M) vs BIIB (6.56B). BIIB has higher revenues than NBIX: BIIB (9.94B) vs NBIX (3.1B).
BIIBNBIXBIIB / NBIX
Capitalization27.9B16.6B168%
EBITDA2.7B829M326%
Gain YTD11.34716.37269%
P/E Ratio21.0725.3983%
Revenue9.94B3.1B320%
Total Cash4.28B1.32B325%
Total Debt6.56B406M1,616%
FUNDAMENTALS RATINGS
NBIX vs BIIB: Fundamental Ratings
NBIX
BIIB
OUTLOOK RATING
1..100
4280
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
42100
SMR RATING
1..100
4379
PRICE GROWTH RATING
1..100
4348
P/E GROWTH RATING
1..100
8716
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (65) in the Biotechnology industry is in the same range as BIIB (83). This means that NBIX’s stock grew similarly to BIIB’s over the last 12 months.

NBIX's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for BIIB (100). This means that NBIX’s stock grew somewhat faster than BIIB’s over the last 12 months.

NBIX's SMR Rating (43) in the Biotechnology industry is somewhat better than the same rating for BIIB (79). This means that NBIX’s stock grew somewhat faster than BIIB’s over the last 12 months.

NBIX's Price Growth Rating (43) in the Biotechnology industry is in the same range as BIIB (48). This means that NBIX’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for NBIX (87). This means that BIIB’s stock grew significantly faster than NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBNBIX
RSI
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
56%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
62%
Bearish Trend 1 day ago
56%
Momentum
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 14 days ago
56%
Bullish Trend 4 days ago
69%
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 17 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRQR1.480.01
+0.34%
ProQR Therapeutics NV
RYAAY57.16-1.56
-2.66%
Ryanair Holdings plc
TPC72.26-2.03
-2.73%
Tutor Perini Corp
KXIN6.00-0.19
-3.06%
Kaixin Holdings
APOG37.27-1.30
-3.37%
Apogee Enterprises

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+3.78%
PFE - BIIB
51%
Loosely correlated
-0.82%
AMGN - BIIB
50%
Loosely correlated
+3.03%
AZN - BIIB
49%
Loosely correlated
-0.66%
MRK - BIIB
47%
Loosely correlated
-0.82%
BMY - BIIB
41%
Loosely correlated
+0.48%
More

NBIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with TEVA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then TEVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+6.59%
TEVA - NBIX
43%
Loosely correlated
-0.76%
AKBA - NBIX
35%
Loosely correlated
+3.56%
ALKS - NBIX
30%
Poorly correlated
+3.48%
AMRX - NBIX
28%
Poorly correlated
+1.78%
BCRX - NBIX
26%
Poorly correlated
-1.02%
More